Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

被引：17

作者：

Agrawal A. ^{[1
]}

Robertson J.F.R. ^{[1
]}

Cheung K.L. ^{[1
]}

机构：

[1] Professorial Unit of Surgery, City Hospital, University of Nottingham

来源：

World Journal of Surgical Oncology | / 4卷 / 1期

关键词：

Tamoxifen; Advanced Breast Cancer; Ethinylestradiol; Clinical Benefit Rate; Endocrine Agent;

D O I：

10.1186/1477-7819-4-44

中图分类号：

学科分类号：

摘要：

Background: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents. Patients and methods: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with "ethinylestradiol" until they were withdrawn from treatment due to adverse events or disease progression. Results: Twelve patients with a median age of 75.1 years (49.1 - 85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for ≥ 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months. Conclusion: Yet unreported, high dose "ethinylestradiol" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy. © 2006 Agrawal et al; licensee BioMed Central Ltd.

引用

共 18 条

[1]

Lonning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., Mella O.A.H., High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy, Breast Cancer Res Treat, 67, 2, pp. 111-116, (2001)

[2]

Agrawal A., Robertson J.F.R., Kl C., High dose oestrogen (HDE) as an endocrine therapy option for advanced breast cancer (ABC), Eur J Cancer, 37, SUPPL. 5, (2005)

[3]

Hayward J.L., Carbone P.P., Heuson J.C., Assessment of response to therapy in advanced breast cancer, Cancer, 39, pp. 1289-1293, (1977)

[4]

Assessment of response to treatment in advanced breast cancer, Lancet, 2, pp. 38-39, (1974)

[5]

Robertson J.F.R., Willsher P.C., Cheung K.L., Blamey R.W., The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer, European Journal of Cancer, 33, 11, pp. 1774-1779, (1997)

[6]

Cole M.P., Jones C.T., Todd I.D., A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of IC146474, Br J Cancer, 25, 2, pp. 270-275, (1971)

[7]

Heuson J.C., Engelsman E., Blonk-Van Der Wijst J., Maass H., Drochmans A., Michel J., Nowakowski H., Gorins A., Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: An E.O.R.T.C. study, Br Med J, 2, 5973, pp. 711-713, (1975)

[8]

Massidda B., Mascia V., Broccia G., Pasqualucci S., Deplano W., Desogus A., Luxi G., Pellegrini A., Estrogen therapy of advanced breast cancer, Minerva Med, 68, 36, pp. 2509-2516, (1977)

[9]

Beex L., Pieters G., Smals A., Koenders A., Benraad T., Kloppenborg P., Tamoxifen versus ethinyl estradiol in the treatment of post-menopausal women with advanced breast cancer, Cancer Treat Rep, 65, 3-4, pp. 179-185, (1981)

[10]

Ingle J.N., Ahmann D.L., Green S.J., Edmonson J.H., Bisel H.F., Kvols L.K., Nichols W.C., Creagan E.T., Hahn R.G., Rubin J.S.F., Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer, N Engl J Med, 304, 1, pp. 16-21, (1981)

← 1 2 →